Shanghai MicroPort MedBot (Group) Co., Ltd. Stock

Equities

2252

CNE100004QP1

Advanced Medical Equipment & Technology

Market Closed - Hong Kong S.E. 04:08:20 2024-04-26 EDT 5-day change 1st Jan Change
13.3 HKD +3.10% Intraday chart for Shanghai MicroPort MedBot (Group) Co., Ltd. +12.52% -36.21%

Financials

Sales 2024 * 225M 31.04M 243M 42.43M Sales 2025 * 697M 96.22M 753M 132M Capitalization 11.8B 1.63B 12.75B 2.23B
Net income 2024 * -686M -94.67M -741M -129M Net income 2025 * -513M -70.8M -554M -96.79M EV / Sales 2024 * 53.8 x
Net Debt 2024 * 295M 40.7M 319M 55.64M Net Debt 2025 * 793M 109M 856M 150M EV / Sales 2025 * 18.1 x
P/E ratio 2024 *
-18.2 x
P/E ratio 2025 *
-26.2 x
Employees 646
Yield 2024 *
-
Yield 2025 *
-
Free-Float 24.87%
More Fundamentals * Assessed data
Dynamic Chart
Shanghai MicroPort MedBot Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Shanghai Microport Medbot Co., Ltd. Provides Group Earnings Guidance for the Year Ended December 31, 2023 CI
Shanghai MicroPort MedBot Co., Ltd. Approves Board Elections CI
China Approves Surgical Robot Developed by Microport MedBot-Robocath JV MT
Shanghai Microport MedBot Gets Thumbs Up to Launch Toumai Surgical Robot MT
Shanghai Microport Medbot Co., Ltd. Announces Toumai Laparoscopic Surgical Robot Obtains Approval from the National Medical Products Administration of China for Multidisciplinary Registration CI
China Approves Launch of MedBot's Orthopedic Surgical Robot MT
Shanghai MicroPort MedBot's Skywalker Hip and Knee Arthroplast Surgical Robot Obtains Launch Approval from National Medical Products Administration of China CI
Shanghai MicroPort MedBot Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
MedBot's Orthopedic Surgical Robot Gets Nod to Enter Australian Market MT
MedBot Obtains European Union's CE Mark for Laparoscope MT
Shanghai Microport Medbot's Prostate Biopsy System Wins Regulatory Nod to Launch MT
Shanghai MicroPort MedBot Co., Ltd. Announces Skywalker Orthopedic Surgical Robot Obtained the ANVISA Certification in Brazil CI
Sunac China working to secure funding to complete projects, chairman says RE
Shanghai MicroPort MedBot Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
More news
1 day+3.10%
1 week+12.52%
Current month-1.04%
1 month-1.04%
3 months-0.15%
6 months-16.14%
Current year-36.21%
More quotes
1 week
12.02
Extreme 12.02
13.42
1 month
11.40
Extreme 11.4
13.60
Current year
9.68
Extreme 9.68
21.35
1 year
9.68
Extreme 9.68
25.10
3 years
9.68
Extreme 9.68
73.45
5 years
9.68
Extreme 9.68
73.45
10 years
9.68
Extreme 9.68
73.45
More quotes
Managers TitleAgeSince
President 40 17-10-17
Comptroller/Controller/Auditor 45 22-05-31
Human Resources Officer 46 21-02-28
Members of the board TitleAgeSince
Chairman 48 20-04-02
Director/Board Member 43 20-09-16
Director/Board Member 41 20-09-16
More insiders
Date Price Change Volume
24-04-26 13.3 +3.10% 507,700
24-04-25 12.9 +2.22% 385,500
24-04-24 12.62 +3.61% 449,294
24-04-23 12.18 +1.33% 356,876
24-04-22 12.02 +1.69% 409,000

Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am

More quotes
Shanghai MicroPort Medical Robot Group Co Ltd is a company engaged in the development of surgical instruments. The Company's main business is the design, development and commercialization of innovative surgical robots. The Company's products include Toumai Laparoscopic Surgical Robot, DFVision 3D Electronic Laparoscope and Honghu Orthopedic Surgical Robot. The Company's surgical robots are used in multiple minimally invasive surgery fields, including endoscopic surgery, orthopedic surgery, pan-vascular surgery, natural cavity surgery and percutaneous puncture surgery. In addition, the Company also provides education and training services for its surgical robot MedBot.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
12.31 CNY
Average target price
21.26 CNY
Spread / Average Target
+72.69%
Consensus

Annual profits - Rate of surprise